buy surpris updat on-going fight
trial broader pipelin track head near-
messag report result increment pipelin updat mostli
in-lin expect includ surpris updat relat on-going gastric
cancer fight trial prompt addit futil analysi earli
mix view could potenti introduc addit uncertainli trial
hand significantli increas potenti market size success
pipelin updat includ near-term data expect in-lin prior guidanc
maintain buy rate updat estim reflect result
surpris updat relat on-going fight trial ad futil
analysi screen patient major present
overexpress without gene amplif recal fight trial
evalu bemarituzumab front-lin gastric cancer partnership
zlab plan enrol patient interim efficaci analysi major
patient identifi via rather ctdna suggest receptor
over-express absenc gene amplif contrast compani
expect posit patient ctdna
posit given distribut among possibl subgroup ihc-posit
ctdna-posit chang expect design trial
compani incorpor futil analysi schedul earli prior interim
efficaci view updat introduc addit uncertainti potenti
expand elig patient popul significantli
antibodi track read monotherapi safeti see
schedul esmo phase expans cohort full mg/kg dose
initi februari full dose keytruda combin cohort start
may
program proceed track without updat guidanc fusion
protein initi phase ia dose escal novemb remain
track read asset out-licens antibodi
cabiralizumab antibodi continu progress
updat model base result maintain buy pt finish
cash cash equival invest
page analyst certif import disclosur
valu per share use dcf base valuat valuat includ lead
product bemarituzumab well probability-adjust cash flow deriv compani
pipelin use discount rate consist commerci stage biotech compani
coverag termin growth rate appli termin year post-assum
risk includ regulatori commerci setback potenti emerg new competitor
/or lower product sale expect risk intellectu properti risk manag
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
